Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ventaira Pharmaceuticals

Request full access

Specialty pharmaceutical company leveraging science and engineering for more effective medicines

Columbus, United StatesFounded 2000Biotech & Life Sciences

About Ventaira Pharmaceuticals

Ventaira Pharmaceuticals, formerly known as BattellePharma, was a specialty pharmaceutical company established in 1997 and spun out from the Battelle Memorial Institute in 2000. The company focused on developing pharmaceutical products for inhalation to treat pulmonological diseases. The core of its operations was a proprietary drug delivery technology called Mystic™, an electrohydrodynamic (EHD) aerosolization process. This electronic nebulization technique applied an electrical field to a conductive liquid, creating a soft mist aerosol designed to deliver drugs more efficiently to and through the lungs.

The company's pipeline included inhaled drugs such as fentanyl for breakthrough pain and salmeterol for asthma. Ventaira's primary business strategy involved leveraging its Mystic™ technology to improve the delivery of new or existing drugs, aiming to create more effective treatments. One of its development programs involved a study with fluticasone propionate, a common asthma treatment, using the Ventaira Phoenix device, which demonstrated a high proportion of medicated aerosol delivery to the lungs for a hand-held device. The company's President and CEO was Leslie Williams.

Ventaira Pharmaceuticals was venture-capital-backed, raising a total of $39.5 million from investors including Battelle Ventures, Early Stage Partners, Fletcher Spaght Ventures, and Merlin BioMed Group. The company secured significant funding rounds, including $25 million in a Series B round in February 2003 and $13.5 million in a Series C round in October 2005. Despite its technological advancements and funding, Ventaira announced in October 2007 that its assets would be acquired by its parent organization, Battelle. Following the acquisition, Ventaira's clinical development programs and device development work were discontinued, and the company ceased operations by the end of 2007.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2000
Headquarters
Columbus, United States
Employees
6
Open positions
None listed
Dealroom signal
22.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Oct 2007 $0 — Battelle Memorial Institute —
SERIES C✓Equity / VC Apr 2005 $14M $54M Fletcher Spaght Ventures · Reservoir Venture Partners · TL Ventures · Battelle Ventures —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Ventaira Pharmaceuticals website traffic

Latest recorded traffic for Ventaira Pharmaceuticals is 240 monthly website visits. Ventaira Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits240 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ventaira Pharmaceuticals in the Columbus ecosystem

Live from Dealroom

The Ventaira Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Pfizer
  • TL Ventures
  • Merlin Biomed
  • Battelle Memorial Institute
  • Fletcher Spaght Ventures
  • Richardson Capital

Series B and later4 investors entered at this stage

  • Reservoir Venture Partners
  • Battelle Ventures
  • Safeguard Scientifics
  • Novitas Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Columbus HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ventaira Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ventaira Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.